Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1994 1
1995 2
1996 1
1998 1
2002 1
2003 1
2004 2
2005 6
2006 6
2007 2
2008 2
2009 6
2010 7
2011 5
2012 8
2013 20
2014 11
2015 19
2016 18
2017 11
2018 7
2019 9
2020 7
2021 5
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

161 results
Results by year
Filters applied: . Clear all
Page 1
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.
Sakamoto S, Kataoka K, Kondoh Y, Kato M, Okamoto M, Mukae H, Bando M, Suda T, Yatera K, Tanino Y, Kishaba T, Hattori N, Taguchi Y, Saito T, Nishioka Y, Kuwano K, Kishi K, Inase N, Sasaki S, Takizawa H, Johkoh T, Sakai F, Homma S; Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Sakamoto S, et al. Eur Respir J. 2021 Jan 5;57(1):2000348. doi: 10.1183/13993003.00348-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 32703779 Free article. Clinical Trial.
BACKGROUND: A randomised controlled trial in Japan showed that inhaled N-acetylcysteine monotherapy stabilised serial decline in forced vital capacity (FVC) in some patients with early idiopathic pulmonary fibrosis (IPF). ...CONCLUSIONS: Combina …
BACKGROUND: A randomised controlled trial in Japan showed that inhaled N-acetylcysteine monotherapy stabilised serial decline …
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20. N Engl J Med. 2012. PMID: 22607134 Free PMC article. Clinical Trial.
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic pulmonary fibrosis. ...CONCLUSIONS: Increased risks of death and hospitalization were observed in patients with …
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for i
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.
Pitre T, Mah J, Helmeczi W, Khalid MF, Cui S, Zhang M, Husnudinov R, Su J, Banfield L, Guy B, Coyne J, Scallan C, Kolb MR, Jones A, Zeraatkar D. Pitre T, et al. Thorax. 2022 Dec;77(12):1243-1250. doi: 10.1136/thoraxjnl-2021-217976. Epub 2022 Feb 10. Thorax. 2022. PMID: 35145039
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor prognosis. ...Only sildenafil probably reduces acute exacerbation and hospitalisations (moderate certainty). Corticosteroids+azathioprine+N-acetylcysteine incr …
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor prognosis. ...Only sildenafil pro …
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Rogliani P, et al. Pulm Pharmacol Ther. 2016 Oct;40:95-103. doi: 10.1016/j.pupt.2016.07.009. Epub 2016 Jul 29. Pulm Pharmacol Ther. 2016. PMID: 27481628 Review.
BACKGROUND: The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year. Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received only a conditional recommendation for use and, thus, to date no drugs are stro …
BACKGROUND: The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year. Pirfenidone and nintedanib …
Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits.
Rushworth GF, Megson IL. Rushworth GF, et al. Pharmacol Ther. 2014 Feb;141(2):150-9. doi: 10.1016/j.pharmthera.2013.09.006. Epub 2013 Sep 28. Pharmacol Ther. 2014. PMID: 24080471 Review.
N-acetyl-l-cysteine (NAC) has long been used therapeutically for the treatment of acetaminophen (paracetamol) overdose, acting as a precursor for the substrate (l-cysteine) in synthesis of hepatic glutathione (GSH) depleted through drug conjugation. Ot
N-acetyl-l-cysteine (NAC) has long been used therapeutically for the treatment of acetaminophen (paracetamol) overdose,
Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review.
Calverley P, Rogliani P, Papi A. Calverley P, et al. Drug Saf. 2021 Mar;44(3):273-290. doi: 10.1007/s40264-020-01026-y. Epub 2020 Dec 16. Drug Saf. 2021. PMID: 33326056 Free PMC article. Review.
N-Acetylcysteine (NAC) is widely used in respiratory medicine, with a maximum licensed dose in chronic use of 600 mg/day; however, some clinical trials have studied the efficacy of NAC at higher doses. ...Most of the studies used oral NAC and were conducted on patie
N-Acetylcysteine (NAC) is widely used in respiratory medicine, with a maximum licensed dose in chronic use of 600 mg/day; howe
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Canestaro WJ, Forrester SH, Raghu G, Ho L, Devine BE. Canestaro WJ, et al. Chest. 2016 Mar;149(3):756-66. doi: 10.1016/j.chest.2015.11.013. Epub 2016 Jan 13. Chest. 2016. PMID: 26836914 Review.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing interstitial lung disease of unknown origin. ...CONCLUSIONS: Although two treatments have been approved for IPF on the basis of reduced decline in pulmonary func …
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing interstitial lung disease of …
Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Sun T, Liu J, Zhao W. Sun T, et al. Medicine (Baltimore). 2016 May;95(19):e3629. doi: 10.1097/MD.0000000000003629. Medicine (Baltimore). 2016. PMID: 27175674 Free PMC article. Review.
There are a number of conflicting reports describing the clinical outcomes of using N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis. We have, therefore, performed a meta-analysis to evaluate the efficacy of N-acetyl
There are a number of conflicting reports describing the clinical outcomes of using N-acetylcysteine for the treatment of i
[Idiopathic pulmonary fibrosis].
Cottin V, Cordier JF. Cottin V, et al. Presse Med. 2008 Nov;37(11):1581-90. doi: 10.1016/j.lpm.2008.01.024. Epub 2008 May 16. Presse Med. 2008. PMID: 18486432 Review. French.
Idiopathic pulmonary fibrosis is a chronic disorder characterized histopathologically by a pattern of usual interstitial pneumonia, with heterogeneous and mutilating interstitial fibrosis with foci of proliferating fibroblasts, honeycomb lung, and litt
Idiopathic pulmonary fibrosis is a chronic disorder characterized histopathologically by a pattern of usual interstitia
Japanese guideline for the treatment of idiopathic pulmonary fibrosis.
Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, Date H, Taniguchi H, Nakayama T, Nishioka Y, Hasegawa Y, Hattori N, Fukuoka J, Miyamoto A, Mukae H, Yokoyama A, Yoshino I, Watanabe K; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Homma S, et al. Respir Investig. 2018 Jul;56(4):268-291. doi: 10.1016/j.resinv.2018.03.003. Epub 2018 Jul 3. Respir Investig. 2018. PMID: 29980444 Review.
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology which accounts for a large proportion of cases of idiopathic interstitial pneumonia. ...
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology which accounts for a large proportion of cases of
Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis: A prospective, single-arm study.
Okuda R, Matsushima H, Oba T, Kawabe R, Matsubayashi M, Amano M, Nishizawa T, Honda K. Okuda R, et al. Respir Investig. 2016 May;54(3):156-61. doi: 10.1016/j.resinv.2015.10.001. Epub 2015 Dec 15. Respir Investig. 2016. PMID: 27108010 Clinical Trial.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with few treatment options. ...(UMIN title: Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis, UMIN000016706, 2015/ …
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with few treatment options. ...(UMIN titl …
Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes.
Salisbury ML, Lynch DA, van Beek EJ, Kazerooni EA, Guo J, Xia M, Murray S, Anstrom KJ, Yow E, Martinez FJ, Hoffman EA, Flaherty KR; IPFnet Investigators. Salisbury ML, et al. Am J Respir Crit Care Med. 2017 Apr 1;195(7):921-929. doi: 10.1164/rccm.201607-1385OC. Am J Respir Crit Care Med. 2017. PMID: 27767347 Free PMC article.
OBJECTIVES: To evaluate AMFM and visual quantification of HRCT patterns and their relationship with disease progression in idiopathic pulmonary fibrosis. METHODS: Patients with idiopathic pulmonary fibrosis in a clinical trial of predniso …
OBJECTIVES: To evaluate AMFM and visual quantification of HRCT patterns and their relationship with disease progression in idiopathic
Is N-acetylcysteine effective in the treatment of pulmonary fibrosis?
Jeldres Pulgar A, Labarca G. Jeldres Pulgar A, et al. Medwave. 2016 Sep 29;16(Suppl3):e6555. doi: 10.5867/medwave.2016.6555. Medwave. 2016. PMID: 27689534 English, Spanish.
Idiopathic pulmonary fibrosis is a progressive chronic respiratory disease that in final stages carries high mortality. ...We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded N-
Idiopathic pulmonary fibrosis is a progressive chronic respiratory disease that in final stages carries high mortality.
161 results